Prima Biomed in trading halt
Tuesday, 17 November, 2009
Cancer treatment specialist pharmceutical company, Prima Biomed (ASX:PRR), has requested a trading halt on its shares until November 19 pending an announcement regarding the development its oral vaccine for cervical cancer.
Prima Biomed's flagship product is CVac, which is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of ovarian cancer.
Prima Biomed has had a stellar year on the markets. It began the year around $0.005 and rose around 3,200% to its current price.
Prima Biomed shares were last trading at 16.5c.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
